Nightingale Health to publish Financial Statements Release for financial year July 2022–June 2023 on 28 September 2023
Press release, 14 September 2023 at 2:30 p.m. (EEST)
Nightingale Health Plc will publish its financial statements release for the financial year July 2022–June 2023 on 28 September 2023 at around 9 a.m. EEST. Materials will be made available soon after publication at www.nightingalehealth.com/investors.
Nightingale Health will arrange a live webcast for investors and media in English on 28 September 2023 at 2 p.m. EEST. You can watch the webcast online at https://nightingalehealth.videosync.fi/2022-2023-results.
The strategy update announced on 11 September 2023 will also be presented during the webcast.
A presentation will held by CEO Teemu Suna and CFO Tuukka Paavola. A recording of the event will be available later the same day at www.nightingalehealth.com/investors.
For further information, please contact:
Nightingale Health Investor Relations
[email protected]
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
